
## Brigida Anna Maiorano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/202268/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review. Immunotherapy, 2022, 14, 65-75.	1.0	6
2	Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective. Seminars in Cancer Biology, 2022, 86, 997-1007.	4.3	8
3	Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives. International Journal of Molecular Sciences, 2022, 23, 820.	1.8	15
4	Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day. Biomedicines, 2022, 10, 411.	1.4	11
5	The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy. International Journal of Molecular Sciences, 2022, 23, 3871.	1.8	14
6	Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience. Diagnostics, 2022, 12, 685.	1.3	1
7	Immunotherapy in advanced anal cancer: Is the beginning of a new era?. Cancer Treatment Reviews, 2022, 105, 102373.	3.4	12
8	How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review. Frontiers in Oncology, 2022, 12, 844801.	1.3	7
9	Efficacy of immune checkpoint inhibitors in different types of melanoma. Human Vaccines and Immunotherapeutics, 2021, 17, 4-13.	1.4	19
10	Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis. Pharmaceuticals, 2021, 14, 476.	1.7	16
11	Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities. Vaccines, 2021, 9, 623.	2.1	17
12	Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives. Cancers, 2021, 13, 4438.	1.7	40
13	Biomarkers of response to advanced prostate cancer therapy. Expert Review of Molecular Diagnostics, 2020, 20, 195-205.	1.5	12
14	The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients' Age: A Systematic Review and Meta-Analysis. Journal of Immunotherapy, 2020, 43, 95-103.	1.2	7
15	Proteomics of Pancreatic Neuroendocrine Tumors: A Systematic Review. Protein and Peptide Letters, 2020, 27, 1276-1287.	0.4	2
16	Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?. Cancers, 2019, 11, 1055.	1.7	40
17	First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome. Frontiers in Endocrinology, 2019, 10, 365.	1.5	1
18	Conjunctival Melanoma: Genetic and Epigenetic Insights of a Distinct Type of Melanoma. International Journal of Molecular Sciences, 2019, 20, 5447.	1.8	29

#	Article	IF	CITATIONS
19	Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions. Critical Reviews in Oncology/Hematology, 2019, 139, 83-86.	2.0	7
20	Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma. Frontiers in Oncology, 2019, 9, 232.	1.3	31